Niagen Bioscience, Inc.
NAGE
$4.78
-$0.04-0.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.74% | 26.85% | -28.72% | -29.47% | 282.27% |
| Total Depreciation and Amortization | 2.05% | -0.51% | 0.51% | 3.17% | -6.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.12% | 9.95% | 3,223.21% | 98.56% | -527.19% |
| Change in Net Operating Assets | -22.14% | 30.20% | -260.54% | -47.54% | 916.10% |
| Cash from Operations | -81.61% | 195.36% | -84.14% | -8.16% | 145.58% |
| Capital Expenditure | -320.83% | 82.22% | -321.88% | 53.62% | -68.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -320.83% | 82.22% | -321.88% | 53.62% | -228.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 50.00% | -33.33% | 0.00% | -50.00% | 50.00% |
| Issuance of Common Stock | 50.00% | -95.95% | 20.49% | -17.86% | 263.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 0.00% | 85.37% | -- |
| Cash from Financing | -154.05% | -96.05% | 20.55% | -17.16% | 260.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -86.95% | -21.45% | -55.66% | -10.65% | 171.70% |